Enanta Pharmaceuticals, Inc.
Enanta Pharmaceuticals, Inc.（ENTA）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · ENTA · 截至 2026年6月8日
活动摘要
买入笔数
1
P-Purchase only
卖出笔数
9
近12个月
买卖比
0.11
Buy/Sell (by trades)
整体情绪
Enanta Pharmaceuticals, Inc.内部人在过去近12个月主要在卖出股份，卖出行为通常由预设的Rule 10b5-1计划驱动，不一定代表对公司的负面看法。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月8日
ENTA 季度内部人买卖趋势
ENTA 内幕交易卖出 · ENTA 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 8, 2026
活跃内部人
近12个月交易最活跃 · ENTA CEO内幕交易
显示全部内部人 · 点击卡片过滤下方交易表
▸ 按reportingName聚合 · 近12月交易次数Top5 · 无额外API
近期内幕交易记录
ENTA 高管卖出股份 · ENTA 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| Feb 12, 2026 | Kowalsky Matthew Paul Chief Legal Officer | Award | 4,175 | — | Form 4 |
| Feb 12, 2026 | Kowalsky Matthew Paul Chief Legal Officer | Other | 1,902 | $27K | Form 4 |
| Feb 12, 2026 | Kowalsky Matthew Paul Chief Legal Officer | Award | 1,318 | — | Form 4 |
| Feb 12, 2026 | Luu Brendan Chief Business Officer | Award | 4,987 | — | Form 4 |
| Feb 12, 2026 | Luu Brendan Chief Business Officer | Other | 3,257 | $46K | Form 4 |
| Feb 12, 2026 | Luu Brendan Chief Business Officer | Award | 1,575 | — | Form 4 |
| Feb 12, 2026 | Kieffer Tara Lynn Chief Product Strategy Officer | Award | 4,987 | — | Form 4 |
| Feb 12, 2026 | Kieffer Tara Lynn Chief Product Strategy Officer | Other | 3,257 | $46K | Form 4 |
| Feb 12, 2026 | Kieffer Tara Lynn Chief Product Strategy Officer | Award | 1,575 | — | Form 4 |
| Feb 12, 2026 | Rottinghaus Scott T. Chief Medical Officer | Award | 5,225 | — | Form 4 |
| Feb 12, 2026 | Rottinghaus Scott T. Chief Medical Officer | Other | 3,413 | $49K | Form 4 |
| Feb 12, 2026 | Rottinghaus Scott T. Chief Medical Officer | Award | 1,650 | — | Form 4 |
| Feb 12, 2026 | Or Yat Sun Chief Scientific Officer | Award | 5,225 | — | Form 4 |
| Feb 12, 2026 | Or Yat Sun Chief Scientific Officer | Other | 3,413 | $49K | Form 4 |
| Feb 12, 2026 | Or Yat Sun Chief Scientific Officer | Award | 1,650 | — | Form 4 |
| Feb 12, 2026 | Luly Jay R. President and CEO · Director | Award | 15,200 | — | Form 4 |
| Feb 12, 2026 | Luly Jay R. President and CEO · Director | Other | 6,155 | $88K | Form 4 |
| Feb 12, 2026 | Luly Jay R. President and CEO · Director | Award | 4,800 | — | Form 4 |
| Dec 5, 2025 | Capps Kathleen S. See Remarks | Sale | 323 | $5K | Form 4 |
| Dec 5, 2025 | Trout Harry R. III See Remarks | Sale | 542 | $8K | Form 4 |
| Dec 5, 2025 | Rottinghaus Scott T. Chief Medical Officer | Sale | 798 | $11K | Form 4 |
| Dec 5, 2025 | Luu Brendan Chief Business Officer | Sale | 1,394 | $20K | Form 4 |
| Dec 5, 2025 | Kieffer Tara Lynn Chief Product Strategy Officer | Sale | 2,106 | $30K | Form 4 |
| Dec 5, 2025 | Or Yat Sun Chief Scientific Officer | Sale | 2,390 | $34K | Form 4 |
| Dec 5, 2025 | Luly Jay R. President and CEO · Director | Sale | 4,743 | $67K | Form 4 |
Kieffer Tara Lynn
Chief Product Strategy Officer
日期
Feb 12
股数
3,257
均价
$14.25
总金额
$46K
Kieffer Tara Lynn
Chief Product Strategy Officer
日期
Dec 5
股数
2,106
均价
$14.23
总金额
$30K
⚡ = 金额≥$100万 · Award/Option价格显示— · 仅Form4 · 仅普通股
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 ENTA 内幕交易
ENTA 内幕交易
Enanta Pharmaceuticals, Inc.（ENTA）内幕交易数据来源于公司内部人（包括Luu Brendan (Chief Business Officer), Kieffer Tara Lynn (Chief Product Strategy Officer), Rottinghaus Scott T. (Chief Medical Officer)）提交的SEC Form 4申报文件。过去12个月内，5位内部人向SEC提交了交易申报。ENTA内部人近期主要在卖出，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看Enanta Pharmaceuticals, Inc.机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
ENTA 内幕交易 · 5个问题Enanta Pharmaceuticals, Inc.（ENTA）的内部人包括高管和董事，如Luu Brendan (Chief Business Officer), Kieffer Tara Lynn (Chief Product Strategy Officer), Rottinghaus Scott T. (Chief Medical Officer)等。过去12个月内，5位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 8, 2026